Acquirers Don't Buy Your Device, They Buy Your Market Position
May 25, 2026
Olympus Corporation just agreed to pay $270 million for a balloon filled with saline… Take a moment with that.
At $14.5 million in sales, that’s more than an 18x on a times-revenue basis. For what is, mechanically speaking, one of the simplest devices you can imagine.
But BioProtect did things right, and it shows.
The problem they solved is enormous. Prostate cancer is the second most diagnosed cancer in men worldwide, with 1.5 million new cases a year. Radiation treatment works, but other critical anatomy surrounds the prostate and takes collateral damage. Bowel, urinary, and sexual function all can be affected. That's not a mild annoyance, that's a quality of life issue affecting a lot of men.
The solution is about as elegant as it gets. A preformed, biodegradable balloon that creates consistent space between the prostate and rectum during radiation, then resorbs on its own within six months. Saline inflated and no removal procedure, simple.
And the clinical proof is there. Four-year follow-up data showed statistically significant improvements in patient-reported sexual function. It’s the first spacer of its kind to demonstrate that. That's not a feature in a crowded field, that puts this device in a category by itself.
The IP is real and it's been proven, twice. This is a bit of icing on the cake, but the same core biodegradable polymer technology already sold once when BioProtect’s spin-off, OrthoSpace, was acquired by Stryker in 2019. They essentially had two exits from one technology platform, smart.
Just like Stryker and OrthoSpace, the acquirer fit this time is hand in (surgical) glove. Olympus already calls on urologists. BioProtect works right into their sales channels.
So no, Olympus didn't pay 18x revenue for a balloon. They paid for a defensible position in a large market, with clinical evidence that holds up, IP that's hard to replicate, and a product their sales team can sell tomorrow.
The device is simple. The strategy behind it wasn't.
Support for MedTech at Every Stage
Archimedic partners with medical device teams to solve complex design, development, regulatory, and go-to-market challenges.
